Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition

Brasil Notícia Notícia

Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition
Brasil Últimas Notícias,Brasil Manchetes

Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.

Biogen will pay $172.50 per share in cash for Reata, which had a Thursday closing price of $108.

55), andThe company was founded in Plano, Texas in 2002 and focuses on antioxidative and anti-inflammatory drugsBiogen, a Massachusetts-based biotech company with a market cap of nearly $38 billion, has acquired three other companies in the last eight years. The $200 million

 

Brasil Últimas Notícias, Brasil Manchetes



Render Time: 2025-01-10 15:32:58